Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today said it was
pleased with the U.S. Food and Drug Administration (FDA)’s
Cardiovascular and Renal Drugs Advisory Committee’s recommendation for
approval of vorapaxar. Vorapaxar is the company’s investigational
antiplatelet medicine for the reduction of atherothrombotic events, when
added to standard of care, in patients with a history of heart attack
and no history of stroke or transient ischemic attack.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Cardiology | Cardiovascular | Food and Drug Administration (FDA) | Heart | Heart Attack | Ischemic Stroke | Merck | Pharmaceuticals | Stroke